The Danish pharmaceutical company Novo Nordisk has notified Roszdravnadzor that it will stop supplying the Rebelsas drug to Russia for patients with diabetes from 2024. It is reported by RBC with reference to the press service of the department.
“During the three months of 2023, 9,240 packages of the Rebelsas medicine were released into civilian circulation, deliveries will continue until the end of the year,” the report says.
At the same time, the Russian market, noted in Roszdravnadzor, there are analogues of this drug with international non-proprietary names exenatide, dulaglutide and liraglutide.
At the end of March, Roszdravnadzor warned that by the end of 2023, supplies of another drug for diabetics, Ozempika, would stop. It is also manufactured by Novo Nordisk.
After the start of the military operation in Ukraine, the Danish company did not announce a complete withdrawal from Russia. Nevertheless, the first reports of a shortage of Ozempic appeared already in March last year.
According to Rosstat, more than 5 million patients with diabetes are officially registered in Russia.
Source: Rosbalt
Mario Twitchell is an accomplished author and journalist, known for his insightful and thought-provoking writing on a wide range of topics including general and opinion. He currently works as a writer at 247 news agency, where he has established himself as a respected voice in the industry.
